Moderna Competitors and Similar CompaniesClear all
Moderna's competitors and similar companies include Regulus Therapeutics and Alnylam.
 Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2010 | Founding Date 2007 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations San Diego, US HQ | ||
Employees | Employees 5,60044% increase | Employees 2462% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 21.2 b | Valuation ($) 105.4 m | Valuation ($) 36.5 b |
Financial | |||
Revenue (est.) | Revenue (est.) $3.2b (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $2.2b (FY, 2024) |
Cost of goods | Cost of goods $1.5b (FY, 2024) | Cost of goods N/A | Cost of goods $306.5m (FY, 2024) |
Gross profit | Gross profit $1.8b (FY, 2024) | Gross profit N/A | Gross profit $1.9b (FY, 2024) |
Net income | Net income ($3.6b) (FY, 2024) | Net income ($46.4m) (FY, 2024) | Net income ($278.2m) (FY, 2024) |
Operating ⚠ | |||
Patents Issued | Patents Issued 270 (FY, 2020) | Patents Issued 300 (FY, 2016) | Patents Issued N/A |
Funding | |||
Total funding raised | Total funding raised $ 1.8b | Total funding raised $ 10m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Regulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company